A 76-year-old womansuffered from somnolence while fasting for almost 2 years. Fasting plasma glucose (FPG) (40 mg/dl) and the immunoreactive insulin (IRI) level (8.8
Introduction
It is often difficult to confirm that hypoglycemia results from insulinoma. Neither Fajan' s (IRI/FPG) or Turner' s (IRIxlOO/ (PG-30)) ratios for hormonal assessment nor imaging diagnostics such as angiography or dynamic computedtomography (CT) provide sufficiently high sensitivity for the diagnosis of insulinoma. Imaging techniques are frequently unable to detect a significant percentage of insulinomas [CT, 52.4%; angiography, 69.5%; ultrasound (US), 43.9%; magnetic resonance imaging (MRI), 72.7%]. Such difficulty may be due to characteristics of insulinoma; 81.1% of cases are within 2 cm in size, with a 6.6% rate of metastases, and 12.6% of cases have multiple lesions (1) .
This report describes a case in which a secretin test (2) was used to diagnose an insulinoma, and Selective Arterial Calcium Infusion test (SACI) (3) was used for assessing location and function of the tumor. The secretin test was also used postsurgically to confirm complete resection of tumor and to assess the recovery of remaining (3 cell function.
Case Report
A 76-year-old womansuffered from somnolence before breakfast for almost 2 years. The morning somnolence occurred about once in two months. Normalconsciousness was consistently recovered following sugar intake. No remarkable past history was found. She had one son whohad diabetes treated with voglibose for 5 years. In June 2000, the patient was admitted to Osaka City Kita Hospital for evaluation of her morning, pre-prandial somnolence. Early in the morning, her fasting plasma glucose (FPG) was 31 mg/dl and her immunoreactive insulin (IRI) was 7.0 jiU/ml. Insulinoma was suspected and she was brought to our hospital for further evaluation. Onadmission, she was alert and oriented. Physical findings were normal, other than mild obesity (height, 166 cm; weight, 58 kg; BMI, 25.6). At 3 AM on her second hospital day, PG was 40 mg/dl and IRI was 8.8 jLiU/ml. Plasma IRI level was not sufficiently high to apply the classical criteria for insulinoma, Fajan' s ratio (IRI/PG^0.3) or Turner's ratio (IRIxl00/(PG-30)^200). Counterregulatory hormones including cathecholamines, glucagon, thyroid hormone and growth hormone were within normal limits. During episodes of hypoglycemia, the patient moved sluggishly. However, she exhibited no other symptomsof hypoglycemia, such as diaphoresis, tremor or palpitations. no increase in plasma IRI, a finding compatible with insulinoma. Dynamic CT scanning revealed a 12-mmhypervascular tumor in the head of the pancreas. To insure accurate preoperative tumor localization and to further assess tumor function, a selective arterial calcium injection (SACI) test was performed, via the transcutaneous femoral artery (Fig. 2) . This test is usually performed at the time of selective abdominal arteriography. A 5-ml bolus of 0.025 mEq Ca2+/kg of calcium gluconate diluted with saline was injected into each of the following: the gastroduodenal artery (GDA), superior mesenteric artery (SMA), splenic artery (SA), and right hepatic artery (RHA). Blood samples from the right hepatic vein were taken prior to and at 30, 60, 90 and 120 seconds post-injection in order to measure IRI levels. A marked increase in IRI levels was observed in the GDAand SMA,with no change in IRI levels in the SA and RHA (Fig. 2) . These results suggested an insulinoma located on the head of pancreas, with no metastases to other locations, such as the tail of the pancreas or the liver. Simultaneous angiography showed a single tumor fed by both the GDA and SMA. Enucleation of the tumor was performed on the twentieth hospital day. Plasma glucose level recovered to within the normalrange soonafter the enucleation. Noepisode of hypoglycemia was observed after the operation. Onthe eighteenth postoperative day, a glucagon test showed the normal IRI response. Administration of 75 g OGTTrevealed an IGT pattern. On the twenty-first postoperative day, a secretin test was performed, prompting an almost 5-fold increase in IRI levels, suggesting a normal (3 cell response. Pathohistological examination revealed the tumor to be an islet cell adenoma. Immunohistological examination showedthat the tumor expressed insulin, but not glucagon, somatostatin, or gastrin.
Discussion
In recent years, it has been reported that hormonal data in manycases of insulinoma maynot be compatible with the classical Fajan's ratio or Turner's ratio (4) . This may be due to the specificity of the antibody used for measurement. Because the antibodies used might not distinguish between insulin and proinsulin, the IRI level may be overestimated. Thus, it may prove difficult to diagnose and localize insulinoma using conventional hormonal studies alone. Furthermore, in our case, the patient's fasting IRI levels were not elevated sufficiently to definitively diagnose insulinoma.
After surgery, 75g OGTTshowed impaired glucose tolerance (IGT) pattern, with hypersecretion and prolongation of insulin before surgery. This may be due to: 1) insufficiency of recovery of (3 cell function which was suppressed by insulinoma,
2) insulin resistance due to obesity as a result of glucose administration for prevention of hypoglycemia, 3) diabetogenic state, concerning of her family history. It is well knownthat secretin stimulates p cells to release useful for differential diagnosis of insulinoma and (3 cell hyperplasia (5) . Figure 3 summarizes the results of the secretin tests used by both Imamuraet al and ourselves. In our patient, after enucleation of the tumor, there wasa normalinsulin secretion in response to secretin. The peak value of IRI in postoperative patients returns to the same level as that of healthy subjects. The use of this test assumes that normal (3 cells release insulin when stimulated by secretin, while insulinoma cells do not respond in vivo or in vitro (5) . The lack of response against secretin mayrepresent that the secretin receptor in the p cells in the insulinoma-bearing pancreas are under downregulation in the condition of insulin hypersecretion. After extirpation of the tumor, normal (3 cell function is recovered, as revealed by the secretin test. These findings indicate that the secretin test is useful for both the preoperative diagnosis of insulinoma and for the postoperative confirmation of total insulinoma resection. In addition, the secretin test can be repeated during the pre-and postoperative stage in a non-invasive manner.
Because preoperative localization of pathologic sources of hyperinsulinism is reported to fail in as manyas 40-60% of cases, and because 10%of insulinomas are reported to be multiple and malignant (1), it is very important to carefully and accurately localize insulinoma prior to surgery. The noninvasive modalities of ultrasound, CT, and MRIoften fail to demonstrate insulinomas smaller than 15 mmin diameter (6) . SACI was developed by Imamura et al and Doppmanet al in 1990 (2, 6) and is now considered a primary diagnostic tool for assessing the location and function of insulinoma, replacing the use of percutaneous transhepatic portal venous sampling (PTVS) (7) (8) (9) (10) (11) (12) . Compared with PTVS, SACI is less invasive and more sensitive (96.6% versus 87.1%). Currently, the best curative treatment for insulinoma is complete resection. Therefore, it is indispensable to perform SACI, which supplies both accurate localization and highly refined sensitivity before surgery (12, 13).
In conclusion, careful diagnosis and localization of insulinoma is best obtained using the secretin test followed by SACI.
Furthermore, administering the secretin test after tumor resection is valuable in the determination of residual (3 cell function.
